X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1089) 1089
pyrimidinones - administration & dosage (761) 761
male (719) 719
index medicus (648) 648
female (577) 577
lopinavir (492) 492
pyrimidinones - therapeutic use (460) 460
animals (458) 458
adult (427) 427
pyrimidinones - pharmacology (404) 404
hiv infections - drug therapy (383) 383
middle aged (339) 339
pharmacology & pharmacy (319) 319
ritonavir - administration & dosage (297) 297
pyrimidinones - adverse effects (287) 287
pyrimidinones - pharmacokinetics (256) 256
hiv protease inhibitors - administration & dosage (229) 229
infectious diseases (223) 223
treatment outcome (223) 223
aged (216) 216
drug therapy, combination (214) 214
ritonavir - therapeutic use (199) 199
rats (187) 187
mice (176) 176
administration, oral (172) 172
anti-hiv agents - administration & dosage (155) 155
hiv protease inhibitors - therapeutic use (155) 155
pyridones - administration & dosage (147) 147
drug administration schedule (145) 145
dose-response relationship, drug (141) 141
oncology (141) 141
pharmacokinetics (141) 141
ritonavir (140) 140
drug therapy (132) 132
melanoma - drug therapy (131) 131
hiv (130) 130
viral load (130) 130
immunology (126) 126
ritonavir - adverse effects (125) 125
pyrimidinones - chemistry (119) 119
mutation (118) 118
melanoma (116) 116
research (114) 114
anti-hiv agents - therapeutic use (112) 112
hiv protease inhibitors - adverse effects (112) 112
hiv infections - virology (109) 109
hiv-1 - drug effects (109) 109
imidazoles - administration & dosage (107) 107
therapy (107) 107
drug combinations (105) 105
oximes - administration & dosage (103) 103
antineoplastic combined chemotherapy protocols - therapeutic use (99) 99
ritonavir - pharmacokinetics (98) 98
virology (98) 98
protease inhibitors (94) 94
cancer (92) 92
dosage and administration (90) 90
pyrimidinones - blood (87) 87
adolescent (86) 86
care and treatment (85) 85
drug interactions (82) 82
hiv protease inhibitors - pharmacokinetics (82) 82
proto-oncogene proteins b-raf - genetics (82) 82
antiviral agents (81) 81
microbiology (80) 80
analysis (78) 78
antiretroviral therapy (78) 78
lopinavir/ritonavir (78) 78
sulfonamides - administration & dosage (77) 77
cell line, tumor (76) 76
thymidine - analogs & derivatives (76) 76
time factors (76) 76
chemistry, medicinal (74) 74
health aspects (74) 74
article (73) 73
disease models, animal (73) 73
skin neoplasms - drug therapy (73) 73
adenine - analogs & derivatives (71) 71
antiretroviral therapy, highly active (71) 71
resistance (71) 71
trametinib (67) 67
young adult (67) 67
cd4 lymphocyte count (65) 65
pyridones - adverse effects (65) 65
safety (65) 65
tenofovir (65) 65
area under curve (64) 64
hiv-1 (63) 63
prospective studies (63) 63
reverse transcriptase inhibitors - administration & dosage (63) 63
anti-hiv agents - adverse effects (62) 62
proto-oncogene proteins b-raf - antagonists & inhibitors (62) 62
rats, sprague-dawley (62) 62
hepatitis b, chronic - drug therapy (61) 61
pyrimidinones - chemical synthesis (61) 61
vemurafenib (61) 61
dogs (60) 60
melanoma - genetics (60) 60
pyridines - administration & dosage (60) 60
structure-activity relationship (58) 58
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1295) 1295
Spanish (27) 27
German (21) 21
Japanese (21) 21
Russian (7) 7
Chinese (5) 5
French (3) 3
Czech (2) 2
Danish (1) 1
Hungarian (1) 1
Italian (1) 1
Korean (1) 1
Polish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


AIDS, ISSN 0269-9370, 09/2007, Volume 21, Issue 14, pp. 1899 - 1907
Objectives: To describe first dose and steady state antiretroviral drug exposure in the female genital tract. Design: Non-blinded, single center, open-label... 
Women | Genital tract | HIV | Prophylaxis | Sexual transmission | Pharmacokinetics | Antiretroviral therapy | genital tract | INFECTIOUS DISEASES | sexual transmission | antiretroviral therapy | EMTRICITABINE | IMMUNOLOGY | CEREBROSPINAL-FLUID | prophylaxis | BACTERIAL VAGINOSIS | PROTEASE INHIBITOR | TRICHOMONAS-VAGINALIS | HIV-INFECTION | THERAPY | VIROLOGY | LIQUID-CHROMATOGRAPHY | SIMIAN IMMUNODEFICIENCY VIRUS | pharmacokinetics | MACAQUES | women | Lamivudine - administration & dosage | Humans | Deoxycytidine - blood | Zidovudine - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Genitalia, Female - metabolism | Emtricitabine | HIV Infections - blood | HIV Protease Inhibitors - blood | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Administration, Oral | Anti-Retroviral Agents - pharmacokinetics | Deoxycytidine - administration & dosage | Lopinavir | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Pyrimidinones - blood | Anti-Retroviral Agents - administration & dosage | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Zidovudine - blood | Deoxycytidine - analogs & derivatives | Reverse Transcriptase Inhibitors - blood | Zidovudine - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | HIV Infections - drug therapy
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2008, Volume 52, Issue 7, pp. 569 - 576
Journal Article
The Lancet, ISSN 0140-6736, 2006, Volume 368, Issue 9534, pp. 476 - 482
Lopinavir-ritonavir is a preferred protease inhibitor co-formulation for initial HIV-1 treatment. Fosamprenavir-ritonavir has shown similar efficacy and safety... 
MEDICINE, GENERAL & INTERNAL | THERAPY | NAIVE PATIENTS | RECOMMENDATIONS | EFAVIRENZ | TENOFOVIR DF | RESISTANCE | AIDS | SOCIETY-USA PANEL | LOPINAVIR/RITONAVIR | NELFINAVIR | Dideoxynucleosides - administration & dosage | Organophosphates - administration & dosage | Lamivudine - administration & dosage | Ritonavir - administration & dosage | HIV-1 - drug effects | Humans | Lopinavir | Pyrimidinones - therapeutic use | Organophosphates - therapeutic use | Carbamates - administration & dosage | HIV Protease Inhibitors - administration & dosage | HIV-1 - genetics | Reverse Transcriptase Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Sulfonamides - therapeutic use | Lamivudine - therapeutic use | Ritonavir - therapeutic use | HIV Infections - drug therapy | Dideoxynucleosides - therapeutic use | Pyrimidinones - administration & dosage | Reverse Transcriptase Inhibitors - therapeutic use | Carbamates - therapeutic use | Drug Therapy, Combination | Sulfonamides - administration & dosage | Dosage and administration | Protease inhibitors | Comparative analysis | Drug therapy | HIV infection | Antiviral agents | Research | Drug therapy, Combination | Health aspects | Anti-HIV agents | Antiretroviral drugs | Human immunodeficiency virus--HIV | Samples | Clinical trials | Comparative studies | Clinical medicine | Disease control
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2008, Volume 359, Issue 21, pp. 2233 - 2244
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2014, Volume 71, Issue 6, pp. 1102 - 1109.e1
Background BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) frequently cause cutaneous adverse events. Objective We sought to investigate the cutaneous safety... 
Dermatology | cutaneous adverse event | rash | histology | inflammation | therapy | squamous cell carcinoma | squamous cell carcinoma therapy | ACTIVATION | IMPROVED SURVIVAL | OPEN-LABEL | DERMATOLOGY | METASTATIC MELANOMA | MEK INHIBITION | PATHWAY | RESISTANCE | RAF INHIBITORS | MUTATIONS | VEMURAFENIB | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Skin Neoplasms - drug therapy | Follow-Up Studies | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Young Adult | Pyridones - administration & dosage | Carcinoma, Squamous Cell - mortality | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Retrospective Studies | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Kaplan-Meier Estimate | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Azetidines - administration & dosage | Carcinoma, Squamous Cell - drug therapy | Indoles - adverse effects | Melanoma - drug therapy | Piperidines - adverse effects | Adolescent | Sulfonamides - adverse effects | Aged | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma - mortality | Complications and side effects | Medical colleges | Melanoma
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 07/2017, Volume 28, Issue 7, pp. 1631 - 1639
Background: Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination... 
trametinib | melanoma | durable outcomes | BRAF | metastatic | dabrafenib | MULTICENTER | OPEN-LABEL | COMBINATION | TRIAL | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | POOLED ANALYSIS | NIVOLUMAB | IPILIMUMAB | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - pharmacokinetics | Oximes - adverse effects | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Pyridones - administration & dosage | Time Factors | Melanoma - genetics | Skin Neoplasms - mortality | Protein Kinase Inhibitors - pharmacokinetics | Skin Neoplasms - pathology | Double-Blind Method | Drug Administration Schedule | Pyridones - pharmacokinetics | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Melanoma - secondary | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Pyrimidinones - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Original
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 03/2010, Volume 53, Issue 3, pp. 323 - 332
BACKGROUND:Once-daily atazanavir/ritonavir demonstrated similar antiviral efficacy to twice-daily lopinavir/ritonavir over 48 weeks, with less gastrointestinal... 
CASTLE study | HIV-1 | Combination antiretroviral therapy | Atazanavir/ritonavir | Treatment-naive patients | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | ADULTS | IMMUNOLOGY | REGIMENS | ADHERENCE | HIV-INFECTED PATIENTS | THERAPY | DIDANOSINE | EFAVIRENZ | DRUGS | atazanavir/ritonavir | SAQUINAVIR/RITONAVIR | combination antiretroviral therapy | treatment-naive patients | Humans | Middle Aged | Male | RNA, Viral - blood | Oligopeptides - adverse effects | Viral Load | Anti-HIV Agents - administration & dosage | Tenofovir | Young Adult | Pyridines - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | HIV-1 - isolation & purification | Lipids - blood | Aged, 80 and over | Atazanavir Sulfate | Adult | Deoxycytidine - adverse effects | Female | Antiretroviral Therapy, Highly Active - methods | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Ritonavir - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Lopinavir | Pyrimidinones - adverse effects | Organophosphonates - adverse effects | Treatment Outcome | Adenine - administration & dosage | Organophosphonates - administration & dosage | Adolescent | HIV Infections - drug therapy | Aged | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Deoxycytidine - analogs & derivatives
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 773 - 781
Journal Article
PLOS ONE, ISSN 1932-6203, 05/2015, Volume 10, Issue 5, p. e0125021
The aim of combination drug treatment in cancer therapy is to improve response rate and to decrease the probability of the development of drug resistance.... 
COLON-CANCER | MELANOMA | MEK INHIBITION | TYROSINE KINASE | MULTIDISCIPLINARY SCIENCES | SYNTHETIC LETHAL INTERACTION | RESISTANCE | BRAF | KINASE INHIBITOR | BETA-CATENIN | EGFR | Triazoles - administration & dosage | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Oximes - administration & dosage | Imidazoles - administration & dosage | Aza Compounds - pharmacology | Cell Line, Tumor - drug effects | Indazoles - administration & dosage | Quinolines - administration & dosage | Indoles - administration & dosage | Quinolines - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Melanoma - genetics | Indoles - pharmacology | Pyrimidinones - pharmacology | Molecular Targeted Therapy - methods | Proto-Oncogene Proteins B-raf - metabolism | Proto-Oncogene Proteins p21(ras) - metabolism | Aza Compounds - administration & dosage | Imidazoles - pharmacology | Melanoma - pathology | Sulfonamides - pharmacology | Proto-Oncogene Proteins c-myc - metabolism | beta Catenin - metabolism | beta Catenin - genetics | Indazoles - pharmacology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Triazoles - pharmacology | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Oxazoles - administration & dosage | Oximes - pharmacology | Benzimidazoles - pharmacology | Cell Proliferation - drug effects | Oxazoles - pharmacology | Proto-Oncogene Proteins c-myc - genetics | Pyrimidinones - administration & dosage | Mutation | Pyridones - pharmacology | Sulfonamides - administration & dosage | Drug therapy, Combination | Drug resistance | Drug therapy | Health aspects | Analysis | Melanoma
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 2014, Volume 111, Issue 6, pp. 1141 - 1152
Journal Article